Avadel Pharmaceuticals — Flamel Technologies — Investor Presentation (October 2016)
37 slides from Avadel Pharmaceuticals's investor presentation, Oct 20, 2016
Slide 1: Flamel
FLAMEL
Slide 2: Company Highlights
Company Highlights FLAMEL * Cash flow positive & strong balance sheet — NO DEBT + $84.3 million cash flow from operations generated in 2015 + $154.9 million in cash and marketable securities as of June 30, 2016 * Data for Micropump® applied to sodium oxybate expected 1H 2018 * Current market size in
Slide 3: Corporate Transformation
Corporate Transformation $173.2 millionproduct Epp approved FDAapproved Tevenue; $84million Akovaz™” ‘SPAagreement vazculep® cash from operations reached with FDA Established as drug delivery & formulation company Coreg CR® using Micropump® received FDA approval (GSK partnered product) Acquired FSC
Slide 4: 2016 Expectations
2016 Expectations ¥ Launch Akovaz™ (Approved on 4/29/16) ¥ Y Integrate FSC Pediatrics and optimize sales territories ™ Y Beginlicensing discussions for Trigger Lock™ & Medusa platforms Commence registrati F III trial of Micropump' oxybate by 2H 201 4) FLAMEL 4 UMD is Flamel's Unapproved Marketed Dru
Slide 5: Current Pipeline
Current Pipeline Drug/ Technology Indication Proof of Concept Phase Ill Unapproved Marketed Drug#4 Undisclosed! a> Sodium oxybate/ Panera Narcolepsy Hydromorphone / s P. Trigger Lock™ an Exenatide/Medusa™ Diabetes LiquiTime® Cough/Cold Phase Ill trial for Micropump® sodium oxybate initiated Septembe
Slide 6: Sodium Oxybate Market Opportunity
Sodium Oxybate Market Opportunity >~178,000 narcoleptic patients in U.S.* >150,000 patients not on sodium oxybate therapy Large untapped opportunity exists in narcolepsy patient population Xyrem® FY 2016 sales expected to be $1.095 - $1.130 billion @ * GlobalData & JAZZ’s 4Q’15 earnings call FLAMEL
Slide 7: Micropump Sodium Oxybate (FT218)
Micropump® Sodium Oxybate (FT218) fa Studied in 40 healthy volunteers at 4.5 grams, 6 grams and 7.5 grams Results showed: Similar onset of action as Xyrem Slightly lower Cmax than Xyrem Similar blood levels at hours 7 - 8 FT218 has potential to eliminate 2"4 dose & provide other patient benefits (oe
Slide 8: Phase III Pivotal Trial - FT218
Phase III Pivotal Trial - FT218 * Randomized, double-blind, placebo controlled efficacy study * 264 patients * ~60 clinical sites across U.S., Canada & Eastern Europe & Patients will undergo screening period then be titrated to daily doses of 4.5 g, 6.0 g, 7.5 g and 9.0 g FT218 or placebo Patients o
Slide 9: Micropump Overview
Micropump® Overview Robust platform technology utilizing microparticles for the extended/delayed release of drugs in Gl tract Tailored release profile solves dosing problems related to PK profiles and drugs with short half lives Micropump 1* approved in 2006 in Coreg CR (carvedilol) 10 years — no ge
Slide 10: Trigger Lock abuse-deterrent hydromorphone (FT227)
Studied in 30 healthy volunteers: 3 FT227 prototypes (fasted & fed) Results: 1 formulation bioequivalent to Jurnista® (fasted) Selected formulation to advance @% «+ IMSdata ? “America’s Addiction Abuse-deterrent, extended-release, oral solid for application with opi 3d Prescription ids e” (National
Slide 11: LiquiTime Overview
LiquiTime® Overview Licensed OTC rights to Perrigo in October 2015 — first two products: ° |buprofen = 12 hour profile developed for pain/fever = Regulatory pathway deemed high risk and high cost * Guaifenesin = Successful pilot PK study reported in March 2015 = Second PK study ongoing = Update anti
Slide 12: Medusa Exenatide (FT228)
FLAMEL Medusa™ Exenatide (FT228) Subcutaneous injection formulation of exenatide, a GLP-1 (glucagon-like peptide—1) for treatment of Type 2 diabetes Phase Ib Results rket Opportunity * 1 dose FT228 (140mcg) / week for 4 weeks in 12 type 2 diabetes mellitus patients * PK data showed continuous releas
Slide 13: Marketed Products
Marketed Products Mi A FLAMEL Ostober 2016 b
Slide 14: Eclat Portfolio Products
Eclat Portfolio Products Bloxiverz® (neostigmine methylsulfate injection) * Indication: Reverses neuromuscular blockades used in surgical procedures * lof 3 approved versions; ~ 4 million vials sold annually in the U.S.* Vazculep® (phenylephrine hydrochloride injection) * Indication: Treatment of hy
Slide 15: Pediatric Products
Pediatric Products Karbinalee (carbinoxamine maleate) extended-release oral suspension | 4mg/SmL * Indication: Perennial allergic rhinitis in children 2 years of age and older * Patent protection through March 2029 * Rx antihistamine market size in U.S. ~ $110M CEFACLOR For Oral Suspension, USP 125
Slide 16: Strong Intellectual Property
Strong Intellectual Property —N Patent Protection Throu; Platform us Europe Micropump® July 2027 July 2023 LiquiTime® September 2025 April 2023 Trigger Lock™ April 2027 May 2026 (pending) Medusa™ June 2031 June 2027 (pending) Karbinal™ ER March 2029 AcipHex® Sprinkle™ September 2016 Flexichamber® Ma
Slide 17: Seasoned Senior Management
Seasoned Senior Management Pram etene| Michael S. Anderson Mike Kanan Phillandas T. Thompson Sandy Hatten Gregory J. Davis David Monteith, Ph.D. Dhiren D’Silva A) FLAMEL Chief Executive Officer Senior Vice President and Chief Financial Officer Senior Vice President, General Counsel Senior Vice Presi
Slide 18: GAAP Financial Results
Non- /) FLAMEL GAAP Financial Results “Reconciliations from GAAP to Non-GAAP can be found in the appendix 022016 022016 {in 0005) vs. vs. 022016 12016 _022015 a1 2016 922015, Revenue $ 38858 $36,216 © $ 48,602 2642 $ (9,748) Cost of products and servicessold 345 343 2,756 Research and development ex
Slide 19: GAAP Financial Results
Non- /) FLAMEL GAAP Financial Results “Reconciliations from GAAP to Non-GAAP can be found in the appendix 022016 022016 {in 0005) vs. vs. 022016 12016 _022015 a1 2016 922015, Revenue $ 38858 $36,216 © $ 48,602 2642 $ (9,748) Cost of products and servicessold 345 343 2,756 Research and development ex
Slide 20: Cash Flow Summary
Cash Flow Summary six Months Ended June 30, {in 000s) 2016 2015 TOTAL Cash and Marketable Securities Beginning Balance $ 144,802 $ 92,834 Operating Cash Flows (excludingtax and earnout/royalty payments) 36,816 60,176 Tax Payments (13,100) (20,875) Earnout/Royalty Payments (16,316) (7,008) Repayment
Slide 21: Company Highlights
Company Highlights FLAMEL * Cash flow positive & strong balance sheet — NO DEBT + $84.3 million cash flow from operations generated in 2015 + $154.9 million in cash and marketable securities as of June 30, 2016 * Data for Micropump® applied to sodium oxybate expected 1H 2018 * Current market size in
Slide 22: Appendix
if) FLAMEL Appendix October 2016 A
Slide 23: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations Three MonthsEnded June 30,2016 {in thouzance- 505) Product sales and services License and reresreh revenue Total revenue Cost of products and sevices sold Research and development expenses Intangible asset amortization condiderstion Total opersting expenses Opersting
Slide 24: GAAP Financial Results
GAAP Financial Results {in 0005) Revenue Cost of products and services sold Research and development expenses Selling, general and admin expenses Intangible asset amortization Fairvalue adjustments of contingent consideration Operating expenses Operatingincome (loss) Interest& other expense (nat) In
Slide 25: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations — Three Months Ended March 32,2015, Adjustments {in nouzonae-US08) Fae Trae Contingent Income tax Purchase elated party Contingent expense Intangible Foreign accounting payable rlsted party (benefit asset exchange adjustments fairvalue peysble | relstedto Tota GAAP a
Slide 26: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations inno. Total revenue condiderstion Investment Income Interest Expense party payable Income ta: provision Net Income (Loss) 4) ‘Three MonthsEnded June 30,2015 Adjustments wzande- S05) Eom inca Contingent Income tox related party Contingent expense Intengible Foreign pa
Slide 27: Flamel's Proprietary Drug Delivery Platforms
Flamel’s Proprietary Drug Delivery Platforms Advanced Formulation and Delivery Platforms for Better and Safer Drugs Micropump® LiquiTime® y i rf) 7 FLAMEL Medusa™ Trigger Lock™ Modified/Controlled Abuse Resistant Release of injectable Drugs Modified/Contralled Release Narcotis/Opioid Analgesics @ Mi
Slide 28: Micropump
: ca ' ie . Micropump® ae « Drug Delivery Platform Modified/Controlled Release of Solid Oral Drugs Mi A FLAMEL October 2016 27
Slide 29: Micropump
Micropump® Micropump® allows development of modified and/or controlled release of solid, oral dosage formulations of drugs © Derivative LiquiTime® allows development of modified/controlled release of liquid formulations * Derivative Trigger Leek™ allows development of tamper-esistant modified/contro
Slide 30: Micropump Platform at a Glance
Micropump® Platform at a Glance * Extended/delayed release of drugs throughout GI Tract + Precise pharmacokinetics of single or combination drugs in various formats + Numerous Micropump®-based products have been successfully tested in human clinical trials Commercial stage platform approved in the U
Slide 31: Microparticles for Controlled/Modified Release
Microparticles for Controlled/Modified Release 0 FLAMEL Granules 4 drug granite or layeredneutral core Coating = Diffusion Control ‘pH independent/ dependent “Fm integrity preserved during Gl rack Compressibilty Mechanical properties Flams's MICROPUMP’ technology consists ‘of amultiple-dose system c
Slide 32: LiquiTime
m LiquiTime® — Drug Delivery Platform Modified/Controlled Release of Liquid Oral Drugs Mi dj FLAMEL October 2016 3L
Slide 33: LiquiTime
LiquiTime® See ee * Allows development of modified/controlled release liquid formulations for patients havingissues swallowing tablets/capsules * Not limited to working solely with ionic drugs as with resin-complex based technologies * Readilyscalable to commercial quantities * Easy to swallow, good
Slide 34: Trigger Lock
Trigger Lock™ Platform Abuse Deterrent Extended Release of Opioids Mi A FLAMEL October 2016 3
Slide 35: Trigger Lock for Abuse Deterrence
Trigger Lock™ for Abuse Deterrence ° Drugloaded Micropump® microparticles: Sustained Release (SR) microparticles individually polymer coated which are resistant to crushing * Viscosifying ingredient(s): To prevent abuse by injection after extractionina small volume of solvent * Quenching ingredient(
Slide 36: Medusa
sii Medusa™ H tl i, Drug Delivery Platform Modified/Controlled Release of Injectable Drugs Mi A FLAMEL October 2016 35
Slide 37: In Vivo Drug Release from Medusa Depot
In Vivo Drug Release from Medusa™ Depot Release of the unmodified drug by diffusion, disaggregation of the depot and competition with endogeneous proteins over several days Depot formation - Injection Day Day x* ee ee Natural and safe components disappearing progressively ‘by adjusting polymer conce
Flamel Technologies — Investor Presentation (October 2016) on 6ix